Improving the lives of people suffering from mental illness and substance use disorders

Developing improved pharmaceuticals based on innovative drug delivery technologies

Providing evidence-based digital therapies to improve treatment outcomes

What we do

Pharmaceuticals

Pharmaceuticals

Commercializing and developing pharmaceuticals addressing large unmet needs

Digital Therapeutics

Digital Therapeutics

Product portfolio of scientifically proven digital therapies

Mental illness & substance use disorders

Mental illness & substance use disorders

Focusing on areas of great human suffering with wider societal implications

We Care

Shedding light on lives affected by addiction and the road to recovery

Our mission for our blog platform on which we share the stories and insights from individuals coping with addiction, recovery and mental health.

Key News

APRIL 13, 2021
Report from the Annual General Meeting

MARCH 23, 2021
Publication of 2020 Annual Report

MARCH 17, 2021
ZUBSOLV´s patent portfolio continues to strengthen

Our history

Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.

Orexo Social

12 April 2021

THIS IS BEYOND. Such an inspiring and hopeful story our colleague PSyD Gery-Lynn Utter brings to her important work… https://t.co/LqjD2va8er

8 April 2021

To avoid being captured in the vicious circle of #addiction there is a need of counselling support to cope with AUD… https://t.co/wcpUZLvlap

7 April 2021

Ethypharm acquires the rights to deprexis & vorvida in 4 European countries from our partner @GAIA_COM. Yet another… https://t.co/USDN34EMMN

News Flow

Regulatory Press Releases

Financial Snapshot

Group net revenues

663.6 MSEK

LTM1

Group EBITDA

19.0 MSEK

LTM1

US Pharma segment EBIT

331.2 MSEK

LTM1

Cash position

505.3 MSEK

Q4 2020

1 Last Twelve Months, Q120-Q420, for more information about financial development Link